Company Description
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide.
The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue.
In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization.
It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors.
The company is headquartered in Alachua, Florida.
Contact Details
Address: 13631 Progress Boulevard, Suite 400 Alachua, Florida 32615 United States | |
| Phone | 386 462 6800 |
| Website | axogeninc.com |
Stock Details
| Ticker Symbol | AXGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000805928 |
| CUSIP Number | 05463X106 |
| ISIN Number | US05463X1063 |
| Employer ID | 41-1301878 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Michael D. Dale | President, Chief Executive Officer and Director |
| Marc A. Began | Executive Vice President, General Counsel and Chief Compliance Officer |
| Jens Schroeder Kemp | Chief Marketing Officer |
| Erick DeVinney | Chief Innovation Officer |
| Lindsey Hartley CPA | Chief Financial Officer |
| Craig A. Swandal | Vice President of Operations |
| Harold D. Tamayo M.B.A. | Vice President of Finance and Investor Relations |
| Doris Quackenbush | Vice President of Sales |
| Dr. Ivica Ducic M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 8-K | Current Report |
| Jan 23, 2026 | 8-K | Current Report |
| Jan 23, 2026 | 424B5 | Filing |
| Jan 21, 2026 | 424B5 | Filing |
| Jan 21, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 16, 2025 | 144 | Filing |
| Dec 16, 2025 | 144 | Filing |
| Dec 15, 2025 | 144 | Filing |